Biotech: Page 39
-
PharmaVoice Team/PharmaVoice
The Calendar
Coming Attractions The annual BIO International Convention, June 15-18, 2015, in Philadelphia covers the wide spectrum of life-sciences innovations and application areas. Drug discovery, biomanufacturing, genomics, biofuels, nanotechnology, and cell therapy are just a few of the industries repre...
By PharmaVoice Team • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Talent Pool
Biopharma Pool David Allsop Amicus Therapeutics Appoints Senior VP, International Amicus Therapeutics, a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, has appointed David Allsop as senior VP, international. He is responsible for Amicus’ international organi...
By PharmaVoice Team • June 1, 2015 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Talent Pool
Biopharma Pool Steven Ertel Dr. Matthew Sherman Acceleron Pharma Announces Executive Appointments and Promotions Acceleron Pharma, a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic candidates that regulate cellular growth...
By PharmaVoice Team • May 1, 2015 -
PharmaVoice Team/PharmaVoice
2015 HBA Luminaries
The Importance of Mentoring and Sponsorship Emily Lightfoot. AmerisourceBergen. Relationships with mentors have been the key to my career success. Having an advocate and coach to help me plan my career, discover my strengths, and identify opportunities has helped me develop confidence to take on ...
By Taren Grom • May 1, 2015 -
PharmaVoice Team/PharmaVoice
Pharma Trax
Venture Funding Trends Trending now: Report shows an increase in funding for rare diseases and a decrease in funding for chronic diseases. Seventy-eight percent of U.S. venture investment for therapeutics went toward novel drug R&D, suggesting innovation is a core priority for venture investo...
By PharmaVoice Team • April 1, 2015 -
PharmaVoice Team/PharmaVoice
Talent Pool
Biotechnology Pool Mary Thistle Dimension Names Chief Business Officer Dimension Therapeutics, a rare disease company advancing novel treatments for diverse genetic disorders of the liver based upon an AAV gene therapy platform, has appointed Mary Thistle to the newly created position of chief bu...
By PharmaVoice Team • April 1, 2015 -
PharmaVoice Team/PharmaVoice
Talent Pool
Biotechnology Pool Tony Hunt Repligen Names CEO Repligen, a life-sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs, has appointed Tony Hunt as CEO. Mr. Hunt, currently Repligen’s chief operatin...
By PharmaVoice Team • March 1, 2015 -
PharmaVoice Team/PharmaVoice
Talent Pool
Executive appointments and promotions in the healthcare industry Pharma Pool Dr. Julie Gerberding Merck Strengthens Executive Team Merck has named Julie Gerberding, M.D., as executive VP for strategic communications, global public policy and population health. In this newly created executive comm...
By PharmaVoice Team • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
Last Word
Addressing the Needs of THOSE WITH RARE DISEASES Peter Saltonstall, President and CEO of the National Organization for Rare Disorders (NORD), talks about recent orphan drug approvals. PV: 2014 was a record year for orphan drug approvals. What are your predictions for the orphan drug space for 201...
By Peter Saltonstall • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
R&D Crowdsourcing: Crowdsourcing in Pharma
Companies are looking at nontraditional ways of collaborating to access new insights that could lead to innovative therapies. There is a growing movement within the industry toward open access and crowdsourcing scientific information to accelerate research and development. This open environment r...
By Denise Myshko • Nov. 15, 2014 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: E-Solutions: Power Surge
E-Solutions ranging from mobile advances to EMR technologies are expected to reframe the patient model. Notably, the most encouraging news on mobile and quantified health is the recent announcement and launch of the HealthKit platform and the mobile app Health by Apple. HealthKit allows devices a...
By Taren Grom • Nov. 15, 2014 -
PharmaVoice Team/PharmaVoice
Year in Preview: On the Horizon: Looking Ahead…
Experts from across all sectors of the industry provide their input on the trends in 2015 that will have the biggest impact on the industry, and how they will shape the future of healthcare. For this year’s special Year in Preview issue we took a slightly different tact than in years past. We are...
By Taren Grom • Nov. 15, 2014 -
PharmaVoice Team/PharmaVoice
Talent Pool
Biotech Pool Dr. Annalisa Jenkins Dimension Therapeutics Names CEO Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases, has apppointed Annalisa Jenkins, MBBS, MRCP, CEO. Dr. Jenkins succeeds interim CEO Thomas Beck. Dr. Jenkins brings to Dimensi...
By Ann Grey • Nov. 15, 2014 -
PharmaVoice Team/PharmaVoice
Electronic Health Record: A Focus On Patient Benefits
When we think of the positive impact of electronic health record (EHR) adoption, we often focus on the increased efficiency of the medical practice or additional convenience for healthcare providers (HCPs). We do not often associate those benefits with our most important target: the patient. Curr...
By Eugene Lee • Sept. 27, 2014 -
PharmaVoice Team/PharmaVoice
Embracing Co-Creation to Better Connect
Many patient and caregiver campaigns fail to resonate with their intended audiences. Innovative collaboration methods and co-creation with patients and caregivers can add authenticity to communications and elevate brands. Do you remember the telephone game when you were a kid? One person starts t...
By Dan Bobear • Sept. 27, 2014 -
PharmaVoice Team/PharmaVoice
Transdermal Delivery: Winning Patient Preference
The pharma landscape continues to be crowded and competitive, with more emphasis than ever before on delivering improved patient outcomes at a competitive price. In light of this, pharmaceutical companies must not only deliver products that effectively treat patients’ problems, but also prioritiz...
By Ingrid Blair • Sept. 27, 2014 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: Patient Solutions
As healthcare systems begin to pay for outcomes rather than products, patient-centric solutions and services will play a key role in the race to capture value. From wearables to improved drug delivery devices, from apps to EHR platforms, from patient trackers to packaging, the number of solution...
By Taren Grom • Sept. 27, 2014 -
PharmaVoice Team/PharmaVoice
Vested Outsourcing Imperative
Managing the Talent Supply Chain Large life sciences companies today face many challenges in acquiring and managing talent to meet their business imperatives. The first decision to be made is always the same, whether the workforce contains full-time employees, contingent workers, independent cont...
By Kevin D. Duffy • Sept. 27, 2014 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: Supply Chain: Talent Management: A Different Supply Chain Issue
A sound workforce strategy furthers a company’s business agenda and generates results. When the topic of supply chain management is discussed, the conversation typically is about manufacturing and distribution issues. But today one of the most pressing challenges facing CEOs is the talent supply ...
By Taren Grom • Sept. 27, 2014 -
PharmaVoice Team/PharmaVoice
Colombia Emerges as an Attractive Pharma Market
With a growing interest in attracting R&D and continual economic growth, Colombia is seen as an attractive market for pharmaceutical companies. The Republic of Colombia is evolving from an emerging economy, having enjoyed an economic turnaround since 2000, when it was perceived by economists ...
By Kim Ribbink • Sept. 27, 2014 -
PharmaVoice Team/PharmaVoice
The Education of Principal Investigators
Efforts by pharma companies and other organizations aim to standardize GCP and training requirements for clinical research investigators and sites. Principal investigators and clinical sites are the backbone of clinical research. Sponsors and CROs depend on investigators and sites to conduct stud...
By Denise Myshko • Sept. 27, 2014 -
PharmaVoice Team/PharmaVoice
New Models for Academic Partnerships
Academic medical centers have a renewed interest in partnering with pharmaceutical companies and are investing resources to ensure successful collaborations. Industry partnerships with universities are changing. These collaborations are no longer about single projects. They are broader in scope, ...
By Denise Myshko • Sept. 27, 2014 -
PharmaVoice Team/PharmaVoice
The Nanomedicine Revolution
Nanomedicines have the potential to improve effectiveness and reduce the side effects of therapeutics. Nanotechnology has the potential to revolutionize healthcare across disciplines and specialties. For medicines specifically, nanotechnology can improve drug targeting and effectiveness and reduc...
By Denise Myshko • Sept. 27, 2014 -
PharmaVoice Team/PharmaVoice
In the Pharmacy
As pharmacists’ roles expand to near provider status, new opportunities for partnerships open up for pharma. Over the years, pharmacists’ duties have been expanding, but recent legislative acts and regulations are providing the stimulus for an even more robust role. Pharmacists are becoming full ...
By Robin Robinson • Sept. 27, 2014 -
PharmaVoice Team/PharmaVoice
Last Word
The HBA Turns 35 Laurie Cooke, CEO of the Healthcare Businesswomen’s Association (HBA), discusses the organization’s strategic mission for the future as it celebrates its 35th anniversary. PV: The HBA was originally conceptualized 37 years ago by five women and became an official nonprofit orga...
By Laurie Cooke • Sept. 27, 2014
Previous
